LianBio

LianBio (LIANY) showed zero cyber incidents and zero red-flag 8-K filings (bankruptcy, delisting, restatement, or officer departures) over the last 90 days, suggesting near-term operational stability. However, low signal in a 90-day window does not mean low risk; biotech companies face structural vulnerabilities including dilution from financing rounds and clinical-stage cash burn that our 90-day snapshot cannot capture. The full $49 Report extends analysis to 12 months of SEC filings, calculates a dilution risk score based on equity issuance patterns, maps 8-K context and financing history, and flags AI-driven risk signals tied to pipeline and capital structure. This deeper view is essential for biotech investors evaluating both near-term solvency and long-term shareholder value erosion.